Futibatinib (TAS-120), a highly selective pan-FGFR inhibitor, has activity against FGFR2 resistance mutations [43] and has shown promising clinical activity in FGFR-aberrant iCCA patients in an early-phase study, including in patients progressing on prior FGFR inhibitors. The gene discussed is FGFR2; the disease is infantile convulsions and choreoathetosis.